The expert discussion meeting on phase II/III clinical trial protocols for Deuremidevir Hydrobromide (VV116) dry suspension for the treatment of Respiratory Syncytial Virus infection in infants and young children was successfully held
On November 2, 2023, an expert discussion meeting on the Phase II/III clinical trial protocol for the treatment of respiratory syncytial virus (RSV) infection in infants and young children with deuremidevir hydrobromide (VV116) was successfully held at Shulan (Hangzhou) Hospital, adopting a combination of online and offline.
